Sepracor Inc. (SEPR) is in the Pharma Industry

• Sort by

• KAPLAN THALER NABS $300M LUNESTA BIZ.(News)(Kaplan Thaler Group tapped by Sepracor Inc. for the marketing of its sleep-aid brand Lunesta)(Brief article)

  Byline: rupal parekh Byline: rupal parekh

  Research articles 2008-02-04

  Tags: brand, marketing, Sepracor Inc.

• Sepracor Announces Third Quarter 2006 Operating Results

  MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the third quarter of 2006. For the three months ended September 30, 2006, Sepracor's consolidated revenues were $289.3 million, of which revenues from pharmaceutical product sales were $280.1 million ($138.5 million for sales of XOPENEX([R]) brand...

  Research articles 2006-10-26

  Tags: brand, sales, Sepracor Inc.

• Stock Market Ratings by StockPickReport.com for QUALCOMM, Sepracor, Safeway, NPS Pharmaceuticals and YUM! Brands

  Business Editors

  Research articles 2004-04-27

  Tags: brand, Qualcomm Inc., Safeway Plc., Sepracor Inc., stock, stock market

Additional Resources

• Acorda Therapeutics Names Thomas C. Wessel, M.D., Ph.D., as Chief Medical Officer

  HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Thomas C. Wessel, M.D., Ph.D., has joined the Company as Chief Medical Officer, reporting to Ron Cohen, M.D., President and CEO. In this role, Dr. Wessel will have responsibility for the Company's Clinical Development and Operations, Regulatory Affairs, Biostatistics,...

  Articles 2008-11-12

• Results of Studies of ALVESCO® for the Treatment of Asthma and OMNARIS™ in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting

  * Phase III results show improvements in asthma symptom control for marketed doses of ALVESCO HFA hydrofluoroalkane * ALVESCO HFA treatment shown to be safe and well-tolerated * Ciclesonide in an HFA MDI (metered-dose inhaler) nasal aerosol, in development for treatment of allergic rhinitis, was well-tolerated...

  Articles 2008-11-10

• Zacks Analyst Blog Highlights: Smith International, Inc., WellPoint, Inc., Ltd., Rent-A-Center, Inc., Sepracor Inc. and News Corporation, Inc

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Smith International, Inc. (NYSE: SII), WellPoint, Inc. (NYSE: WLP), Rent-A-Center, Inc....

  Articles 2008-10-30

• Sepracor Inc. Reports 9.6% Increase in Revenue for Third Quarter and Tightens Range for Full-Year 2008 Financial Guidance

  Financial Highlights * Third quarter 2008 revenues increased 9.6% to $307.7 million compared to third quarter 2007 * Reported earnings per share EPS for third quarter 2008 were $0.17 per diluted share vs. $0.34 per diluted share for same period in 2007 * Excluding...

  Articles 2008-10-28

• Britts leaves Sepracor to become Merz president, CEO

  Jack Britts has been appointed president and chief executive officer of Merz Pharmaceuticals LLC. A pharmaceutical industry veteran who joins Merz from Sepracor Inc., Britts will oversee the growth of the company's medical dermatology business and establish units to support Merz's aesthetics and neurology pipeline...

  Articles 2008-10-27

• European Medicines Agency Issues Positive Opinion For LUNIVIA® Marketing Authorization Application In Europe

  MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that the EMEA's Committee for Medicinal Products for Human Use CHMP has issued a positive opinion recommending to grant a marketing authorization for LUNIVIA([R]) brand eszopiclone in the European Union EU for the treatment of insomnia. The EU labeling provides for...

  Articles 2008-10-24

• Sepracor Inc. Sets Conference Call and Webcast for Third Quarter Operating Results

  MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its third quarter 2008 financial results on October 28, 2008. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on October 28, 2008 to discuss its third quarter 2008 financial...

  Articles 2008-10-21

• Zacks Sell List Highlights: Sepracor, CRA International, Owens-Illinois and Ciena Corp

  CHICAGO -- Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 Strong Sell: Sepracor, Inc. (NASDAQ: SEPR) and CRA International, Inc. (NASDAQ: CRAI). Further, Zacks...

  Articles 2008-10-01

• New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy

  * Presentation included results of three Phase III studies of eslicarbazepine acetate in more than 1,000 patients with refractory partial epilepsy * Studies demonstrated marked and sustained seizure reduction and significant improvement in quality of life and depressive symptoms over a one-year treatment period * U.S....

  Articles 2008-09-24

• Pulmatrix Appoints John P. Hanrahan Chief Medical Officer

  LEXINGTON, Mass. -- Pulmatrix Inc., a biotechnology company commercializing a broad new class of treatments for respiratory disease, announced today the appointment of John P. Hanrahan, M.D., M.P.H., as Senior Vice President and Chief Medical Officer. Dr. Hanrahan will lead the Company's clinical development programs beginning with Phase II trials...

  Articles 2008-09-18

• Zacks Bull and Bear of the Day Highlights: The Medicines Company, Hibbett Sports, Sepracor, Johnson Controls and ASM International

  CHICAGO -- Zacks Equity Research highlights The Medicines Company (Nasdaq: MDCO) as the Bull of the Day and Hibbett Sports (Nasdaq: HIBB) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Sepracor, Inc. (Nasdaq: SEPR), Johnson Controls (NYSE: JCI) and ASM International N.V. (Nasdaq: ASMI)....

  Articles 2008-09-10

• ALVESCO® Inhalation Aerosol Now Available in U.S. for Treatment of Asthma

  * ALVESCO HFA is a new, inhaled corticosteroid prodrug available in a small-particle hydrofluoroalkane HFA solution * The growing U.S. market for inhaled corticosteroids is estimated at approximately $1.26 billion(1) MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that ALVESCO HFA Inhalation Aerosol MDI (metered-dose...

  Articles 2008-09-08

• LUNESTA® Next-Day Function and Discontinuation Data from a Long-Term 12-Week Study in Elderly Patients Presented at ECNP

  * Elderly patients taking LUNESTA 2 mg showed significant improvements in measures of daytime function compared to placebo over a 12-week treatment period * Elderly patients administered LUNESTA 2 mg showed no evidence of rebound insomnia and withdrawal symptoms were comparable to the placebo group upon discontinuation ...

  Articles 2008-09-03

• Sepracor Announces Senior Management Appointments

  MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced the appointment of two senior managers to key strategic and operational roles within the organization. Richard Ranieri has been appointed to the newly created position of Executive Vice President, Human Resources and Administration, and Julio Casoy, M.D., has been appointed Senior...

  Articles 2008-08-19

• Sepracor Inc. Reports Second Quarter 2008 Results

  Financial Highlights * Second quarter 2008 revenues increased 6.3% to $294.1 million compared to second quarter 2007 * Reported earnings per share EPS for second quarter 2008 were $3.41 per diluted share vs. $0.04 per diluted share for same period in 2007 * Excluding...

  Articles 2008-07-29

• BellwetherReport.com Analyst Report on CGNX, SEPR, ATHR and PRSC

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

  Articles 2008-07-29

• Sepracor Inc. Sets Conference Call and Webcast for Second Quarter Operating Results

  MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter 2008 financial results on July 29, 2008. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on July 29, 2008 to discuss its second quarter 2008 financial...

  Articles 2008-07-25